Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.763412
Keywords
COVID-19; SARS-CoV-2; rituximab; anti-CD20 therapy; B cell-depletion; B cell immunodeficiency; hyperimmune convalescent plasma; anti-SARS-CoV-2 monoclonal antibodies
Categories
Ask authors/readers for more resources
The study demonstrates significant effects of B cell-depleting agents on adaptive immunity, which should be considered in the selection of SARS-CoV-2 diagnostics and guiding therapeutic approaches. Combination therapeutic strategies may play a crucial role in the setting of B cell immune deficiencies.
B cell-targeting strategies such as rituximab are widely used in B cell hematologic malignancies, rheumatologic and musculoskeletal diseases and a variety of autoimmune disorders. The purpose of this paper is to illustrate how exposure to anti-CD20 treatment profoundly affects B cell functions involved in anti-SARS-CoV-2 immunity and significantly impacts on the clinical and serological course of SARS-CoV-2 infection, long term immunity and vaccine responses. The data presented here suggest that the effects of B cell-depleting agents on adaptive immunity should be taken into account for the proper selection and interpretation of SARS-CoV-2 diagnostics and to guide appropriate therapeutic approaches and protective measures. Combination therapeutic strategies including immunotherapy in association with prolonged antiviral treatment may play a decisive role in the setting of B cell immune deficiencies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available